BioSpace News Archive

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 18th Annual Morgan Stanley Global Healthcare Conference

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has agreed to sell 2,297,794 of its common shares at a price of $10.88 per share to Pfizer Inc. (NYSE: PFE), for gross proceeds of $25.0 million (the “Transaction”).

Endo International plc (NASDAQ: ENDP) announced today that it will participate in the Citi 15th Annual BioPharma Virtual Conference being held September 8-10, 2020.

Tampa General ranks among the top 10 national health care organizations for its dedication in supporting leaders to achieve better health care outcomes.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:

Amwell®, a national telehealth leader, today announced that it has commenced the roadshow for its proposed initial public offering. Amwell has filed a registration statement with the Securities and Exchange Commission (“SEC”) to offer 35,000,000 shares of its Class A common stock to the public

NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the safety and tolerability of SNK01,

Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances.

Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has been featured as one of the Sunday Times 10 Tech Track Ones to Watch 2020.

Calliditas Therapeutics AB announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines.